A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients
Rostami S, Alavi SM, Daghagheleh R, Maraghi E, Hosseini SA
Virology journal · 8 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2024-04-23 · Virol J · vol. 21 · issue 1 · p. 91
- Publisher
- BioMed Central
- Cited
- 7 citations · more than 79% of similar papers · 1.5× the field average
- References
- 54 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Magnesium in Health and Disease · Long-Term Effects of COVID-19 · Sepsis Diagnosis and Treatment
- Keywords
- Medicine, Randomized controlled trial, Magnesium, Internal medicine, Oxygen saturation, Placebo, Clinical trial, Quality of life (healthcare), Oxygen therapy, Respiratory system, Gastroenterology, Oxygen, Nursing, Pathology
- MeSH
- humans, magnesium, tumor necrosis factor-alpha, c-reactive protein, treatment outcome, double-blind method, quality of life, dietary supplements, adolescent, adult, aged, middle aged, iran, female, male, young adult, covid-19, sars-cov-2, covid-19 drug treatment
5 authors
From IR
- Sepideh RostamiAhvaz Jundishapur University of Medical Sciences
- Seyed Mohammad AlaviAhvaz Jundishapur University of Medical Sciences
- Robab DaghaghelehAhvaz Jundishapur University of Medical Sciences
- Elham MaraghiAhvaz Jundishapur University of Medical Sciences
- Seyed Ahmad Hosseini · correspondingAhvaz Jundishapur University of Medical Sciences
Abstract
Background
This study sought to examine the impact of magnesium supplementation on clinical outcomes and biochemical factors among hospitalized patients with COVID-19.
Methods
This double-blind, randomized clinical trial was conducted at Razi Hospital, Ahvaz, Iran, between September 2021 and March 2022. Participants aged 18-70 years with moderate disease severity were enrolled. Magnesium supplementation (300 mg daily) was administered to the intervention group, while the control group received a placebo. Clinical outcomes, including the need for oxygen therapy, oxygen saturation, respiratory rate, fever, hs-CRP and TNF-α levels, as well as quality of life and mental health, were assessed. Blood samples were collected to measure biochemical variables.
Results
The main result was the count of individuals requiring oxygen therapy. Additional outcomes comprised of oxygen saturation, respiratory rate, fever, hs-CRP and TNF-α levels, as well as quality of life and mental health. Out of 64 participants, 60 completed the study. The results showed that magnesium supplementation significantly reduced the number of patients requiring oxygen therapy (9 vs. 14; P 0.05).
Conclusion
The findings suggest that magnesium supplementation may have beneficial effects on clinical outcomes and arterial oxygen saturation in COVID-19 patients. More investigation is necessary to delve into its potential mechanisms and long-term effects on patient outcomes.
Trial registration
This study is registered on Iranian Registry of Clinical Trials (IRCT) under identifier IRCT20210413050957N1. (The registration date: May 1, 2021).
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.